Printer Friendly

CEL-SCI REQUESTS THAT UNITS CEASE TRADING ON NASDAQ SYSTEMS

 CEL-SCI REQUESTS THAT UNITS CEASE TRADING ON NASDAQ SYSTEMS
 ALEXANDRIA, Va., Feb. 27 /PRNewswire/ -- CEL-SCI Corporation (NASDAQ: CELI) today announced that it has asked NASDAQ to cease trading of its Units (NASDAQ: CELIU) effective March 4, 1992. Holders of Units may separately sell the shares of common stock and warrants comprising the Units at any time. The common stock and the warrants both trade on NASDAQ/NMS.
 "We decided to have the trading in the units stopped because they are not listed on NASDAQ/NMS, whereas the common stock and warrants are, and because they add confusion," said Geert Kersten, v.p., operations.
 CEL-SCI Corporation is engaged in the business of developing compounds that boost the immune system to fight diseases. The main focus is on life threatening diseases such as cancer and AIDS.
 -0- 2/27/92
 /CONTACT: Matt Haines of Strategic Growth International, 212-826-9622, or Daryll Strahl, 303-979-5735, both for CEL-SCI Corporation/
 (CELI) CO: CEL-SCI Corporation ST: Virginia IN: SU:


SB -- DC017 -- 3228 02/27/92 11:33 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 27, 1992
Words:171
Previous Article:CENTRAL RESERVE REPORTS SOLID FOURTH QUARTER RESULTS: CLOSES 1991 WITH STRONG PERFORMANCE
Next Article:FIRST REGIONAL BANCORP REPORTS RESULTS
Topics:


Related Articles
CEL-SCI CORPORATION SHARES NOW TRADE IN NASDAQ NATIONAL MARKET
CEL-SCI WINS FINAL ROUND IN EUROPEAN PATENT LITIGATION
CEL-SCI CORPORATION BEGINS ADVANCED CLINICAL STUDY WITH HGP-30 AIDS VACCINE
CEL-SCI GETS NEW STOCK SYMBOL FOR 30 DAYS
CEL-SCI ENTERS INTO AGREEMENT TO GAIN 100% OWNERSHIP OF AIDS TECHNOLOGY
CEL-SCI CORPORATION EXTENDS EXPIRATION DATE OF WARRANTS TRADING AS 'CELIW' UNTIL FEB. 6, 1997
CEL-SCI CORPORATION FILES CONTRACT BREACH AND PATENT INFRINGEMENT LAWSUITAGAINST IMMUNORX AND DR. JOHN HADDEN, A FORMER COLLABORATOR
CEL-SCI RAISED $1.45 MILLION IN MARCH
CEL-SCI Raises $5.0 Million
CEL-SCI Corporation Extends Warrant Date

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters